Sensitivity and specificity of different methods for cystic fibrosis-related diabetes screening: Is the oral glucose tolerance test still the standard?

Journal of Pediatric Endocrinology and Metabolism

Volumn 30, Issue 1, 2017, Pages 27-35

  Mainguy, Catherine ^a   Bellon, Gabriel ^b   Delaup, Véronique ^b   Ginoux, Tiphanie ^c   Kassai Koupai, Behrouz ^c,d   Mazur, Stéphane ^b   Rabilloud, Muriel ^a,d,e,f   Remontet, Laurent ^a,d,e,f   Reix, Philippe ^b,d  

^a HOSPICES CIVILS DE LYON   (France)

^b Resource and Competence Center of Cystic Fibrosis   (France)

^c Inserm   (France)

^d UNIVERSITÉ DE LYON   (France)

^e UNIVERSITÉ LYON 1   (France)

^f LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

Author keywords

continuous glucose monitoring system; cystic fibrosis related diabetes; glucose metabolism; homeostasis model assessment index of insulin resistance; homeostasis model assessment index of cell function; intravenous glucose tolerance test; oral glucose tolerance test

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADOLESCENT; ANALYTICAL EQUIPMENT; ARTICLE; BLOOD GLUCOSE MONITORING; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTINUOUS GLUCOSE MONITORING SYSTEM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED DIABETES; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOCRINE FUNCTION TEST; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE SENSOR; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HOMEOSTASIS MODEL ASSESSMENT INDEX OF BETA CELL FUNCTION; HUMAN; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; ORAL GLUCOSE TOLERANCE TEST; PREDICTIVE VALUE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STANDARD; ANALYSIS; CLINICAL TRIAL; COMORBIDITY; COMPLICATION; FOLLOW UP; FRANCE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; MASS SCREENING; PATHOPHYSIOLOGY; PREVALENCE; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY;

ADOLESCENT; BIOMARKERS; BLOOD GLUCOSE; CHILD; COMORBIDITY; CYSTIC FIBROSIS; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; FRANCE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; MALE; MASS SCREENING; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 85009799656     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2016-0184     Document Type: Article

References (45)

1. Vaincre la Mucoviscidose I. Registre francais de la mucoviscidose-Bilan des donnees 2013. Paris Fr Vaincre Mucoviscid. 2013;
2. Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cyst Fibros 2013;12:318-31.
3. Olivier AK, Yi Y, Sun X, Sui H, Liang B, et al. Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets. J Clin Invest 2012;122:3755-68.
4. Guo JH, Chen H, Ruan YC, Zhang XL, Zhang XH, et al. Glucoseinduced electrical activities and insulin secretion in pancreatic islet β-cells are modulated by CFTR. Nat Commun 2014;5:4420.
5. Lewis C, Blackman SM, Nelson A, Oberdorfer E, Wells D, et al. Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med 2015;191:194-200.
6. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000;162(3 Pt 1):891-5.
7. Kolouskova S, Zemkova D, Bartosova J, Skalicka V, Sumnik Z, et al. Low-dose insulin therapy in patients with cystic fibrosis and early-stage insulinopenia prevents deterioration of lung function: a 3-year prospective study. J Pediatr Endocrinol Metab 2011;24:449-54.
8. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010;33:2697-708.
9. Moran A, Pillay K, Becker DJ, Acerini CL, International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Management of cystic fibrosisrelated diabetes in children and adolescents. Pediatr Diabetes 2014;15(Suppl 20):65-76.
10. Dobson L, Sheldon CD, Hattersley AT. Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet Med 2004;21:691-6.
11. Brodsky J, Dougherty S, Makani R, Rubenstein RC, Kelly A. Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care 2011;34:292-5.
12. Ode KL, Frohnert B, Laguna T, Phillips J, Holme B, et al. Oral glucose tolerance testing in children with cystic fibrosis. Pediatr Diabetes 2010;11:487-92.
13. Leclercq A, Gauthier B, Rosner V, Weiss L, Moreau F, et al. Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients. J Cyst Fibros 2014;13:478-84.
14. Bourdy S, Rabilloud M, Touzet S, Roche S, Drai J, et al. 178 Glucose tolerance in cystic fibrosis patients over a 3-year period (DIAMUCO study). J Cyst Fibros 2015;14:S103.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
16. Okita K, Iwahashi H, Kozawa J, Okauchi Y, Funahashi T, et al. Homeostasis model assessment of insulin resistance for evaluating insulin sensitivity in patients with type 2 diabetes on insulin therapy. Endocr J 2013;60:283-90.
17. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, et al. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes 2004;53:1782-9.
18. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
19. Lee JM, Okumura MJ, Davis MM, Herman WH, Gurney JG. Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study. Diabetes Care 2006; 29:2427-32.
20. Hirschler V, Aranda C, Calcagno M de L, Maccalini G, Jadzinsky M. Can waist circumference identify children with the metabolic syndrome? Arch Pediatr Adolesc Med 2005;159:740-4.
21. Wahrenberg H, Hertel K, Leijonhufvud BM, Persson LG, Toft E, et al. Use of waist circumference to predict insulin resistance: retrospective study. Br Med J 2005;330:1363-4.
22. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005;115:e500-3.
23. Gillett MJ. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes: Diabetes Care 2009; 32(7): 1327-1334.
24. Bismuth E, Laborde K, Taupin P, Velho G, Ribault V, et al. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr 2008;152:540-5.
25. Moreau F, Weiller MA, Rosner V, Weiss L, Hasselmann M, et al. Continuous glucose monitoring in cystic fibrosis patients according to the glucose tolerance. Horm Metab Res 2008;40:502-6.
26. Schiaffini R, Brufani C, Russo B, Fintini D, Migliaccio A, et al. Abnormal glucose tolerance in children with cystic fibrosis: the predictive role of continuous glucose monitoring system. Eur J Endocrinol 2010;162:705-10.
27. Schmid K, Fink K, Holl RW, Hebestreit H, Ballmann M. Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. J Cyst Fibros 2014;13:80-5.
28. Coriati A, Ziai S, Lavoie A, Berthiaume Y, Rabasa-Lhoret R. The 1-h oral glucose tolerance test glucose and insulin values are associated with markers of clinical deterioration in cystic fibrosis. Acta Diabetol 2016;53:359-66.
29. Sheikh S, Putt ME, Forde KA, Rubenstein RC, Kelly A. Elevation of one hour plasma glucose during oral glucose tolerance testing: 1-hour plasma glucose and cystic fibrosis. Pediatr Pulmonol 2015;50:963-9.
30. Battezzati A, Bedogni G, Zazzeron L, Mari A, Battezzati PM, et al. Age-and sex-dependent distribution of OGTT-related variables in a population of cystic fibrosis patients. J Clin Endocrinol Metab 2015;100:2963-71.
31. Dobson L, Sheldon CD, Hattersley AT. Validation of interstitial fluid continuous glucose monitoring in cystic fibrosis. Diabetes Care 2003;26:1940-1.
32. ORiordan SMP, Hindmarsh P, Hill NR, Matthews DR, George S, et al. Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study. Diabetes Care 2009;32:1020-2.
33. Mohan K, Miller H, Dyce P, Grainger R, Hughes R, et al. Mechanisms of glucose intolerance in cystic fibrosis. Diabet Med 2009;26:582-8.
34. Hammana I, Potvin S, Tardif A, Berthiaume Y, Coderre L, et al. Validation of insulin secretion indices in cystic fibrosis patients. J Cyst Fibros 2009;8:378-81.
35. Elder DA, Wooldridge JL, Dolan LM, DAlessio DA. Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and no prior history of diabetes. J Pediatr 2007;151:653-8.
36. Anzeneder L, Kircher F, Feghelm N, Fischer R, Seissler J. Kinetics of insulin secretion and glucose intolerance in adult patients with cystic fibrosis. Horm Metab Res 2011;43:355-60.
37. Sunni M, Bellin MD, Moran A. Exogenous insulin requirements do not differ between youth and adults with cystic fibrosis related diabetes. Pediatr Diabetes 2013;14:295-8.
38. Cano Megias M, Gonzalez Albarran O, Guisado Vasco P, Lamas Ferreiro A, Maiz Carro L. Insulin resistance, β-cell dysfunction and differences in curves of plasma glucose and insulin in the intermediate points of the standard glucose tolerance test in adults with cystic fibrosis. Endocrinol Nutr 2015;62:91-9.
39. Ode KL. Glucose tolerance in infants and young children with CF. Pediatr Pulmonol 2014;49: S216-456.
40. Fontes G, Ghislain J, Benterki I, Zarrouki B, Trudel D, et al. The F508 mutation in the cystic fibrosis transmembrane conductance regulator is associated with progressive insulin resistance and decreased functional beta-cell mass in mice. Diabetes 2015;64:4112-22.
41. Street ME, Spaggiari C, Ziveri MA, Rossi M, Volta C, et al. Insulin production and resistance in cystic fibrosis: effect of age, disease activity, and genotype. J Endocrinol Invest 2012; 35:246-53.
42. Franzese A, Mozzillo E, Fattorusso V, Raia V, Valerio G. Screening of glucose metabolism derangements in pediatric cystic fibrosis patients: how, when, why. Acta Diabetol 2015;52:633-8.
43. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in patients with cystic fibrosis: five year prospective study. Br Med J 1995;311:655-9.
44. Godbout A, Hammana I, Potvin S, Mainville D, Rakel A, et al. No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes. Diabetes Metab 2008;34:568-73.
45. Boudreau V, Coriati A, Desjardins K, Rabasa-Lhoret R. Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes. J Cyst Fibros 2016;15:258-60.